The study design envisaged enrolling 400 patients in each arm
in a 1:1:1 ratio. However, due the non-availability of one of the
test drugs (M), patients were enrolled initially in a 1:1 ratio in the
G and control regimen arms commencing in May 2004.
Subsequently, when M became available (May 2005) patients
were enrolled to the G, M and control regimen arms in a 1:2:1
ratio to compensate for the delay in recruiting to the moxifloxacin
arm at the onset. Later, on review of interim data, the Data and
Safety Monitoring Board (DSMB) recommended termination of
the G arm initially (February 2006), and later the M arm (October
2006) due to high TB recurrence rates in these two arms compared
to the control regimen arm. Due to the premature termination of
the study, the targeted population of 1200 patients could not be
achieved.